UK Clears Oral Wegovy and Foundation Pledges Europe Research Cash
Regulator approval and a multi‑year foundation fund signal broader access to a pill option and renewed institutional support for cardiometabolic drug discovery.
Overview
- Britain’s MHRA approved the oral Wegovy pill on June 11, 2026 for adults with obesity or overweight who have at least one weight‑related condition, based on Phase 3 OASIS‑4 trial data.
- The Novo Nordisk Foundation announced the CardioMetabolic Bridge program on Friday, June 19, and committed up to DKK 450 million over six years to open incubator labs starting in London to turn academic science into drug projects.
- Stocks reacted to the combined news with a roughly 6.55% one‑day rise on Monday, June 22, and Berenberg’s Kerry Holford raised his price target to DKK 325 while keeping a Buy rating.
- Analysts and reports still flag financial and product risks for Novo Nordisk, noting a growing debt load and heavy revenue concentration in GLP‑1 obesity drugs, while short interest remains low at about 0.51%.
- The pill could make treatment easier for people who avoid injections and may raise prescriptions if payers cover it, and the foundation’s labs could speed new obesity and diabetes therapies — key items to watch are patient uptake, insurer decisions, and competitor responses.